ACTINIUM PHARMACEUTICALS INC (ATNM) Fundamental Analysis & Valuation

NYSEARCA:ATNM • US00507W2061

Current stock price

1.17 USD
-0.02 (-1.68%)
At close:
1.15 USD
-0.02 (-1.71%)
Pre-Market:

This ATNM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ATNM Profitability Analysis

1.1 Basic Checks

  • In the past year ATNM has reported negative net income.
  • ATNM had a negative operating cash flow in the past year.
  • ATNM had negative earnings in each of the past 5 years.
  • In the past 5 years ATNM reported 4 times negative operating cash flow.
ATNM Yearly Net Income VS EBIT VS OCF VS FCFATNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -65.45%, ATNM is doing worse than 62.91% of the companies in the same industry.
  • ATNM has a Return On Equity of -432.56%. This is in the lower half of the industry: ATNM underperforms 77.28% of its industry peers.
Industry RankSector Rank
ROA -65.45%
ROE -432.56%
ROIC N/A
ROA(3y)-58.37%
ROA(5y)-46.97%
ROE(3y)-227.83%
ROE(5y)-153.37%
ROIC(3y)N/A
ROIC(5y)N/A
ATNM Yearly ROA, ROE, ROICATNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ATNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNM Yearly Profit, Operating, Gross MarginsATNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ATNM Health Analysis

2.1 Basic Checks

  • ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ATNM has about the same amount of shares outstanding.
  • ATNM has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ATNM has an improved debt to assets ratio.
ATNM Yearly Shares OutstandingATNM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
ATNM Yearly Total Debt VS Total AssetsATNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • ATNM has an Altman-Z score of -11.93. This is a bad value and indicates that ATNM is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ATNM (-11.93) is worse than 76.31% of its industry peers.
  • There is no outstanding debt for ATNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.93
ROIC/WACCN/A
WACC9.51%
ATNM Yearly LT Debt VS Equity VS FCFATNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • ATNM has a Current Ratio of 6.20. This indicates that ATNM is financially healthy and has no problem in meeting its short term obligations.
  • ATNM's Current ratio of 6.20 is fine compared to the rest of the industry. ATNM outperforms 63.11% of its industry peers.
  • A Quick Ratio of 6.20 indicates that ATNM has no problem at all paying its short term obligations.
  • ATNM's Quick ratio of 6.20 is fine compared to the rest of the industry. ATNM outperforms 63.30% of its industry peers.
Industry RankSector Rank
Current Ratio 6.2
Quick Ratio 6.2
ATNM Yearly Current Assets VS Current LiabilitesATNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ATNM Growth Analysis

3.1 Past

  • ATNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.17%, which is quite good.
  • ATNM shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -55.63% yearly.
EPS 1Y (TTM)14.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-55.63%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ATNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.69% yearly.
  • Based on estimates for the next years, ATNM will show a very strong growth in Revenue. The Revenue will grow by 358.44% on average per year.
EPS Next Y18.59%
EPS Next 2Y22%
EPS Next 3Y12.06%
EPS Next 5Y16.69%
Revenue Next Year-100%
Revenue Next 2Y1367.81%
Revenue Next 3Y721.88%
Revenue Next 5Y358.45%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. ATNM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATNM. In the last year negative earnings were reported.
  • Also next year ATNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNM Price Earnings VS Forward Price EarningsATNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNM Per share dataATNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

  • ATNM's earnings are expected to grow with 12.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22%
EPS Next 3Y12.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATNM Dividend Analysis

5.1 Amount

  • ATNM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATNM Fundamentals: All Metrics, Ratios and Statistics

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (4/29/2026, 8:04:00 PM)

Premarket: 1.15 -0.02 (-1.71%)

1.17

-0.02 (-1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)03-30
Earnings (Next)05-07
Inst Owners20.5%
Inst Owner Change-0.01%
Ins Owners2.35%
Ins Owner Change0%
Market Cap36.70M
Revenue(TTM)90.00K
Net Income(TTM)-33.89M
Analysts81.82
Price Target5.1 (335.9%)
Short Float %3.57%
Short Ratio5.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.22%
Min EPS beat(2)-5.04%
Max EPS beat(2)51.49%
EPS beat(4)2
Avg EPS beat(4)1.16%
Min EPS beat(4)-80.18%
Max EPS beat(4)51.49%
EPS beat(8)5
Avg EPS beat(8)11.4%
EPS beat(12)8
Avg EPS beat(12)10.09%
EPS beat(16)9
Avg EPS beat(16)-3.47%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-17.5%
EPS NQ rev (3m)-17.5%
EPS NY rev (1m)-17.04%
EPS NY rev (3m)-17.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 407.81
P/FCF N/A
P/OCF N/A
P/B 4.69
P/tB 4.69
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -65.45%
ROE -432.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.37%
ROA(5y)-46.97%
ROE(3y)-227.83%
ROE(5y)-153.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.12%
Cap/Sales 115.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.2
Quick Ratio 6.2
Altman-Z -11.93
F-Score4
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)28.36%
Cap/Depr(5y)32.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.76%
EPS Next Y18.59%
EPS Next 2Y22%
EPS Next 3Y12.06%
EPS Next 5Y16.69%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-55.63%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y1367.81%
Revenue Next 3Y721.88%
Revenue Next 5Y358.45%
EBIT growth 1Y13.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.86%
EBIT Next 3Y-9.01%
EBIT Next 5YN/A
FCF growth 1Y25.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.68%
OCF growth 3YN/A
OCF growth 5YN/A

ACTINIUM PHARMACEUTICALS INC / ATNM Fundamental Analysis FAQ

What is the fundamental rating for ATNM stock?

ChartMill assigns a fundamental rating of 3 / 10 to ATNM.


Can you provide the valuation status for ACTINIUM PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to ACTINIUM PHARMACEUTICALS INC (ATNM). This can be considered as Overvalued.


What is the profitability of ATNM stock?

ACTINIUM PHARMACEUTICALS INC (ATNM) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ACTINIUM PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ACTINIUM PHARMACEUTICALS INC (ATNM) is expected to grow by 18.59% in the next year.